What causes cml leukemia

What Causes Chronic Myeloid Leukemia (CML)?

Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the uncontrolled proliferation of granulocytes, a type of white blood cell. Unlike many other cancers, the primary cause of CML is well-understood and is rooted in a specific genetic abnormality.

The Philadelphia Chromosome: The Hallmark of CML

The defining cause of CML is the presence of a genetic mutation known as the Philadelphia chromosome. This is not a chromosome that is passed down from parents to children; rather, it is an acquired genetic change that occurs in a single cell in the bone marrow during a person's lifetime. This acquired mutation is the crucial initiating event in the development of CML.

The Philadelphia chromosome is formed through a process called a reciprocal translocation. In this event, parts of two different chromosomes, specifically chromosome 9 and chromosome 22, break off and switch places. This exchange results in an abnormal chromosome 22, which is the Philadelphia chromosome.

The BCR-ABL Fusion Gene

The critical consequence of the Philadelphia chromosome forming is the creation of a new, abnormal gene called the BCR-ABL fusion gene. This fusion gene is located on the shortened chromosome 22. The BCR-ABL gene produces an abnormal protein, a type of enzyme called a tyrosine kinase. This abnormal tyrosine kinase is overactive and signals the bone marrow cells to produce an excessive number of white blood cells, particularly granulocytes. These immature white blood cells are often referred to as myeloid blasts.

This uncontrolled production of white blood cells crowds out the normal blood cells (red blood cells, platelets, and healthy white blood cells) in the bone marrow. This imbalance leads to the symptoms associated with CML, such as fatigue due to anemia, increased risk of bleeding or bruising due to low platelet counts, and increased susceptibility to infections due to a lack of functional white blood cells.

Acquired vs. Inherited Mutations

It is vital to understand that the genetic mutation causing CML is acquired, not inherited. This means that individuals are not born with the Philadelphia chromosome. It arises spontaneously in a bone marrow stem cell at some point in their lives. This distinguishes CML from many other genetic disorders that are passed down through families.

Risk Factors for CML

While the Philadelphia chromosome is the direct cause of CML, the exact reasons why this specific genetic translocation occurs in some individuals and not others are not fully understood. However, certain factors are known to increase the risk of acquiring genetic mutations that can lead to cancer, including CML:

• Exposure to High Doses of Radiation: Significant exposure to ionizing radiation, such as from atomic bombs or certain radiation therapies, has been linked to an increased risk of developing CML. However, for the vast majority of CML cases, there is no identifiable exposure to high levels of radiation.
• Age: CML is more common in older adults. The average age at diagnosis is around 64 years old. The risk of developing the Philadelphia chromosome mutation increases with age.
• Gender: CML occurs slightly more often in men than in women.

It is important to note that most people diagnosed with CML do not have a history of significant radiation exposure or any other identifiable risk factor. The genetic change appears to happen randomly in a small number of people.

CML and Other Leukemias

CML is one of the major types of leukemia. It is classified as a myeloproliferative neoplasm, meaning it originates from the bone marrow's myeloid cells. CML progresses more slowly than Acute Myeloid Leukemia (AML), another type of leukemia, and is characterized by the presence of mature and immature white blood cells, along with red blood cells and platelets. The Philadelphia chromosome is almost always present in CML, making it a distinct entity among leukemias.

Diagnosis and Treatment Implications

The identification of the Philadelphia chromosome and the BCR-ABL fusion gene has revolutionized the treatment of CML. Unlike many other leukemias where treatment options were historically limited, the development of targeted therapies known as tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes for CML patients. These drugs specifically target the overactive BCR-ABL protein, inhibiting its ability to signal for excessive white blood cell production. This targeted approach has transformed CML from a rapidly fatal disease into a manageable chronic condition for many individuals.

In summary, Chronic Myeloid Leukemia is fundamentally caused by an acquired genetic mutation, the Philadelphia chromosome, which leads to the formation of the BCR-ABL fusion gene. This gene drives the overproduction of white blood cells, forming the basis of the disease. While the exact trigger for this mutation remains unknown in most cases, understanding this specific genetic cause has paved the way for highly effective targeted treatments.